Nick is best known as the founding CEO of Solexa, building and leading the Cambridge-based team that pioneered Next Generation Sequencing (NGS). In 2001, he coined the phrase the '$1,000 genome' to raise awareness of the potential of NGS. In an interview with the BBC in 2002, he predicted a time when an individual's genome sequence would form a part of their medical records.
Nick remains involved with DNA-related technologies, both reading and writing. He is CEO of Longas Technologies, an Australian company turning short-read sequencers into long-read sequencers and a non-exec of Evonetix, a UK company developing next generation DNA synthesis on a microchip.